相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups
Jianguo Li et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2019)
The Novel β-Lactam Enhancer Zidebactam Augments the In Vivo Pharmacodynamic Activity of Cefepime in a Neutropenic Mouse Lung Acinetobacter baumannii Infection Model
S. S. Bhagwat et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia
Shampa Das et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model
Marguerite L. Monogue et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem
David C. Griffith et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
A novel framework to compare the effectiveness of β-lactamase inhibitors against extended-spectrum β-lactamase-producing Enterobacteriaceae
H. Abodakpi et al.
CLINICAL MICROBIOLOGY AND INFECTION (2019)
Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients
Gary E. Stein et al.
SURGICAL INFECTIONS (2019)
Highly variable absorption of clavulanic acid during the day: a population pharmacokinetic analysis
Femke De Velde et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects
Keith A. Rodvold et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Avibactam Pharmacokinetic/Pharmacodynamic Targets
Wright W. Nichols et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
In Vivo Efficacy of Meropenem with a Novel Non-β-Lactam-β-Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model
Marguerite L. Monogue et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
In Vivo Efficacy of Relebactam (MK-7655) in Combination with Imipenem-Cilastatin in Murine Infection Models
Mary Ann Powles et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a beta-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants
Elizabeth G. Rhee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Exploring the Pharmacokinetic/Pharmacodynamic Relationship of Relebactam (MK-7655) in Combination with Imipenem in a Hollow-Fiber Infection Model
Jin Wu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae
Krisztina M. Papp-Wallace et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
An update on beta-lactamase inhibitor discovery and development
Jean-Denis Docquier et al.
DRUG RESISTANCE UPDATES (2018)
Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactann Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234
Krisztina M. Papp-Wallace et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
The Growing Genetic and Functional Diversity of Extended Spectrum Beta-Lactamases
Sadeeq Ur Rahman et al.
BIOMED RESEARCH INTERNATIONAL (2018)
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance A Randomized Clinical Trial
Patrick N. A. Harris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Population Pharmacokinetic Modelling of Ceftazidime and Avibactam in the Plasma and Epithelial Lining Fluid of Healthy Volunteers
Richard Dimelow et al.
DRUGS IN R&D (2018)
Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-beta-Lactamase Inhibitor Combinations
George G. Zhanel et al.
DRUGS (2018)
β-Lactamase inhibitors: what you really need to know
Paul G. Ambrose et al.
CURRENT OPINION IN PHARMACOLOGY (2017)
Pharmacokinetics and Tissue Penetration of Ceftolozane-Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers
Marguerite L. Monogue et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an In Vitro Infection Model
Brian D. VanScoy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae
Olga Lomovskaya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis
Timothy J. Bensman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae
Ghady Haidar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program)
Sibylle H. Lob et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015
Helio S. Sader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection
Johanna Berkhout et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection
Christopher Lucasti et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations
Rachel L. Soon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model
Anthony M. Nicasio et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
In vitro pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms
Sherwin K. B. Sy et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter baumannii
William F. Penwell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City
Amabel Lapuebla et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam
Renu Singh et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: Dosing considerations for Acinetobacter baumannii infections
Yuta Yokoyama et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2015)
Pharmacodynamics of Imipenem in Combination with β-Lactamase Inhibitor MK7655 in a Murine Thigh Model
Eleftheria Mavridou et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Activities of Ceftazidime and Avibactam against β-Lactamase-Producing Enterobacteriaceae in a Hollow-Fiber Pharmacodynamic Model
Ken Coleman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Pharmacokinetic/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in vitro and murine thigh and lung infection models
Yuta Yokoyama et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2014)
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in an In Vitro Infection Model
Brian VanScoy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Pharmacological Basis of β-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with Ceftolozane
Brian VanScoy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients
Mieke Carlier et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases
David E. Ehmann et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Pharmacodynamics of β-Lactamase Inhibition by NXL104 in Combination with Ceftaroline: Examining Organisms with Multiple Types of β-Lactamases
Arnold Louie et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Novel Modeling Framework To Guide Design of Optimal Dosing Strategies for β-Lactamase Inhibitors
Pratik Bhagunde et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Population Pharmacokinetic and Pharmacodynamic Modeling of High-Dose Intermittent Ticarcillin-Clavulanate Administration in Pediatric Cystic Fibrosis Patients
Jeffery T. Zobell et al.
CLINICAL THERAPEUTICS (2011)
Updated Functional Classification of beta-Lactamases
Karen Bush et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Three Decades of beta-Lactamase Inhibitors
Sarah M. Drawz et al.
CLINICAL MICROBIOLOGY REVIEWS (2010)
Sulbactam-containing beta-lactamase inhibitor combinations
M. Akova
CLINICAL MICROBIOLOGY AND INFECTION (2008)
Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units
Juliana F. Roos et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
A review of the antimicrobial activity of clavulanate
J Finlay et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains
MJ Rodríguez-Hernández et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2001)
分享论文
